10 Tirzepatide Telehealth Providers Worth Knowing in 2026

A friend spent three months asking her GP about tirzepatide before she got anywhere. One referral, two denied prior auths, a lot of waiting. Then she found a telehealth option and had a prescription in 48 hours. That gap, between what primary care can do and what a focused online clinic can do quickly, is exactly why tirzepatide telehealth has grown into its own category.

Here are the ten providers that stand out right now, ranked by overall value for most patients.

Comparison Table

Provider	Tirzepatide Starting Price	Compounded?	Insurance Accepted?	Best For
FormBlends	$349/vial	Yes (503A)	No	Peptide + GLP-1 combo seekers, cash-pay
Mochi Health	~$199/mo	Yes	Yes (branded)	Clinical monitoring, obesity medicine MDs
Hims and Hers	~$399/mo (Zepbound)	No (exited 2026)	Yes	App convenience, branded meds
Ro Body	~$149/mo + meds	Depends	Yes	Insurance PA help, polished experience
Henry Meds	~$179-249 mo one	Yes	No	Fast shipping, minimal friction
Found	~$99/mo + meds	Depends	Partial	Coaching plus medication model
Calibrate	Program fee + meds	No	Yes	12-month behavior change focus
PlushCare	~$19.99/mo + meds	No	Yes	Same-day visits, branded scripts
Form Health	~$299/mo + meds	No	Yes	High-touch, dietitian-included care
MEDVi	~$179 first month	Yes	No	No-contract cash simplicity

The Ranked List

1. FormBlends

The strongest all-around pick for cash-pay patients, especially anyone interested in tirzepatide alongside other peptide therapies.

Here is what separates it from every other entry on this list. Most weight-loss telehealth companies sell one thing: GLP-1s. Most peptide suppliers sell research chemicals with no prescription attached. FormBlends is the rare setup where a licensed physician oversees everything, the medication ships from a 503A compounding pharmacy with cGMP standards, and the catalog covers tirzepatide at $349 per vial alongside growth peptides, recovery compounds, nootropics, and longevity protocols. One clinician-supervised roof. That matters for patients who want, say, tirzepatide and BPC-157 (at $54 per vial, with purity certified at 99.2 percent via HPLC, mass spec, and endotoxin testing run on each batch) without bouncing between two separate unvetted vendors.

Pricing is visible before you create an account. No membership layered on top of the medication cost. Cold-chain handling is included in shipping to 47 states. The intake is an online form, a physician reviews it, and you move forward or you don’t. Simple.

Compounded medications are not FDA-approved products. That is a real distinction. But the pharmacy holds FDA-inspected status under the 503A framework, and per-product purity numbers are published, which is more transparency than most compounders offer.

2. Mochi Health

Compounded tirzepatide at around $199 per month, with the option to switch to branded Zepbound when insurance kicks in. What actually distinguishes Mochi is the clinical staff: the company uses board-certified obesity-medicine physicians rather than general telehealth practitioners, so the monitoring is a notch above average. Good fit if you want more than a prescription and a shipping label.

3. Hims and Hers

After a settlement in early 2026, Hims and Hers stopped offering compounded GLP-1s to new patients. Zepbound (branded tirzepatide) now runs about $399 per month through the platform, but if you have commercial insurance plus the Lilly savings card, the out-of-pocket cost can drop dramatically. The app is genuinely smooth. Onboarding is fast. Best for patients who already have or expect insurance coverage.

4. Ro Body

Membership starts around $39 for the first month, then roughly $149 month-to-month or closer to $74 per month on an annual plan, with medication billed separately. Ro’s prior-authorization team is a real feature, not a marketing claim. If you have insurance and you need someone to fight for coverage, Ro invests in that process more than most platforms do.

5. Henry Meds

Fast. That is the thing people say about Henry Meds. Shipping often lands within 24 to 72 hours of approval. The cash-pay compounded program starts around $179 to $249 for month one. The tradeoff is lighter ongoing clinical oversight compared to Mochi or Form Health. Fine for self-directed patients who know what they want.

6. Found

Platform access from about $99 per month, medication billed on top. Found wraps behavioral coaching around the prescription model, which works well for patients who want accountability beyond just the drug. Not the leanest price point once you add medication, but the structure suits people who need more than a monthly refill.

7. Calibrate

Calibrate is built around a year-long commitment. The program fee and medication are priced separately. Heavy emphasis on coaching, habit change, and metabolic education. Best for insured patients who want structured support and are willing to engage with the full program rather than just the injection.

8. PlushCare

At roughly $19.99 per month for app membership, PlushCare is one of the most affordable entry points on this list. It prescribes branded FDA-approved medications, accepts most major insurance plans, and offers same-day appointments. Appointments, laboratory work, and prescription fills are billed separately from the membership fee. Good option if your insurance already covers Mounjaro or Zepbound.

9. Form Health

Premium pricing, premium care. About $299 per month before labs and medication, Form Health pairs each patient with both a physician and a registered dietitian. It is overkill for some patients. For others, especially those with complex metabolic histories, the extra layer of nutrition oversight is exactly what makes the difference.

10. MEDVi

No membership fees. No contracts. Compounded GLP-1 program starting around $179 for the first month, physician review included, 24/7 support line available. It is a clean, uncomplicated cash model that works well for patients who want straightforward access without platform subscriptions piling up.

FAQ

Is compounded tirzepatide legal in 2026?

It depends on the pharmacy’s status and current FDA guidance. Compounded tirzepatide from a licensed 503A pharmacy can be legally dispensed under a valid prescription. Regulations around compounded GLP-1s shifted significantly in early 2026, so confirming your provider’s pharmacy credentials before ordering is worth the five minutes it takes.

How does cash-pay tirzepatide telehealth compare to using insurance?

If your commercial insurance covers Zepbound and you use the Lilly savings card, branded medication can cost less per month than most compounded programs. Cash-pay compounded options make more sense when insurance won’t cover GLP-1s, when you want flexibility without prior authorizations, or when you are combining tirzepatide with other compounds under one program.

What should I look for in a telehealth provider’s compounding pharmacy?

At minimum: 503A or 503B designation, documented batch testing (HPLC purity data, not just a generic certificate of analysis), and a licensed prescriber in the loop. Avoid any platform that ships without a real prescription review.

Are the peptides sold alongside tirzepatide on platforms like FormBlends safe?

The honest answer is that most non-GLP-1 peptides, things like BPC-157, sermorelin, or MK-677, have limited human clinical data. Animal studies and small early-phase trials exist for several of them, but “preclinical evidence” is not the same as established safety and efficacy in humans. A prescriber review matters here more than it does with well-studied medications.

Can I switch providers if my current telehealth platform stops offering compounded tirzepatide?

Yes, and several patients had to do exactly that in early 2026 when some platforms pulled compounded GLP-1s. Transferring a prescription varies by pharmacy, but your medical records and dosing history belong to you. Request them before switching so your new provider has context.

*Before starting any prescription program, run the specifics by a qualified clinician who knows your full health picture. The information here reflects publicly available data as of May 2026 and is editorial opinion, not a substitute for individualized medical evaluation.*